These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24189498)

  • 41. [Therapeutic effect of Ofloxacin on intractable pulmonary tuberculosis. Chest disease cooperative study unit of National Sanatoriums in Kinki District].
    Matsumoto T; Ikeda N; Kanetsuna F; Kita N; Ueda E; Yamazaki M; Kanai K; Sirai F; Iwagaki K; Takenaka K
    Kekkaku; 1988 Jun; 63(6):469-74. PubMed ID: 3172625
    [No Abstract]   [Full Text] [Related]  

  • 42. Tuberculosis. An overview.
    Clarkson EF
    J Intraven Nurs; 1999; 22(4):216-20. PubMed ID: 10476139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy.
    Mortensen NP; Durham P; Hickey AJ
    J Microencapsul; 2014; 31(8):785-95. PubMed ID: 25090595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rifapentine for the treatment of tuberculosis: is it all it can be?
    Gordin FM
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1176-7. PubMed ID: 15161608
    [No Abstract]   [Full Text] [Related]  

  • 45. [Drug resistance of Mycobacteria tuberculosis in patients with new-onset pulmonary tuberculosis].
    Khudushina TA; Voloshina EP; Adamovich NV; Maslakova MG; Terekhova ND
    Probl Tuberk Bolezn Legk; 2005; (12):37-9. PubMed ID: 16496762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis.
    Mitchison DA
    Am J Respir Crit Care Med; 2003 May; 167(10):1298-9. PubMed ID: 12738593
    [No Abstract]   [Full Text] [Related]  

  • 47. [Impact of drug resistance of the causative agent on the outcomes of treatment for pulmonary tuberculosis in the Arkhangelsk Region].
    Tungusova OS; Nizovtseva NI; Toichkina TV; Mar'iandyshev AO; Kaugan DA; Sandven P; Bjune G
    Probl Tuberk Bolezn Legk; 2005; (9):38-43; discussion 43. PubMed ID: 16279517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapy strategy in the treatment of patients with drug-resistant pulmonary tuberculosis].
    Ivanova LA; Pavlova MV; Archakova LI
    Probl Tuberk Bolezn Legk; 2003; (5):14-6. PubMed ID: 12899007
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacoeconomic model of the use of rifabutin in new cases of pulmonary tuberculosis].
    Mednikov BL; Plaksin DI; Piiavskiĭ SA
    Probl Tuberk; 2002; (9):13-7. PubMed ID: 12524980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis.
    Amaral L; Molnar J
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):869-73. PubMed ID: 23030326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of primary tuberculosis in children].
    Bourrillon A
    Pediatrie; 1993; 48(12):888-93. PubMed ID: 8047400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Philip Ellman lecture. The modern management and therapy of pulmonary tuberculosis.
    Fox W
    Proc R Soc Med; 1977 Jan; 70(1):4-15. PubMed ID: 323864
    [No Abstract]   [Full Text] [Related]  

  • 54. [Therapeutic modalities in pulmonary tuberculosis].
    Léophonte P; Didier A; Carré P; Pouchelon E; Rouquet RM
    Rev Prat; 1990 Mar; 40(8):719-24. PubMed ID: 2320896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Short therapy of pulmonary tuberculosis. Reflexions on 2 unusual cases].
    Navarro Gutiérrez R; Iglesias Gómez A
    Rev Clin Esp; 1975 Jul; 138(2):185-8. PubMed ID: 1178965
    [No Abstract]   [Full Text] [Related]  

  • 56. Inhaled Formulation Design for the Treatment of Lung Infections.
    Garcia-Contreras L; Yadav KS
    Curr Pharm Des; 2015; 21(27):3875-901. PubMed ID: 26290199
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hacking into the granuloma: could antibody antibiotic conjugates be developed for TB?
    Ekins S
    Tuberculosis (Edinb); 2014 Dec; 94(6):715-6. PubMed ID: 25287628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The open book of infectious diseases.
    Sassetti CM; Rubin EJ
    Nat Med; 2007 Mar; 13(3):279-80. PubMed ID: 17342136
    [No Abstract]   [Full Text] [Related]  

  • 59. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis.
    Barry CE; Boshoff HI; Dowd CS
    Curr Pharm Des; 2004; 10(26):3239-62. PubMed ID: 15544513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in the development of antimicrobial peptides and proteins for inhaled therapy.
    Wang Y; Chang RYK; Britton WJ; Chan HK
    Adv Drug Deliv Rev; 2022 Jan; 180():114066. PubMed ID: 34813794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.